Literature DB >> 22617823

Infections and vaccines in the etiology of antiphospholipid syndrome.

Paola Cruz-Tapias1, Miri Blank, Juan-Manuel Anaya, Yehuda Shoenfeld.   

Abstract

PURPOSE OF REVIEW: To present scientific evidence supporting the infectious origin for the antiphospholipid syndrome (APS) by molecular mimicry between pathogens, infection and vaccination with β2-glycoprotein I (β2-GPI) molecule. RECENT
FINDINGS: APS is characterized by the presence of pathogenic autoantibodies against β2-GPI. The infection etiology of APS was well established. Likewise, a link between vaccination such as tetanus toxoid may trigger antibodies targeting tetanus toxoid and β2-GPI, due to molecular mimicry between the two molecules. During the years, the pathogenic potential of anti-tetanus toxoid antibodies cross reactive with β2-GPI were found to be pathogenic in animal models, inducing experimental APS.
SUMMARY: Accumulated evidence supports that the presence of anti-β2-GPI antibodies is associated with a history of infections and the main mechanism to explain this correlation is molecular mimicry. The relationship between tetanus toxoid vaccination and APS reveals a novel view on the autoimmune/autoinflammatory syndrome induced by adjuvants (ASIA).

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22617823     DOI: 10.1097/BOR.0b013e32835448b8

Source DB:  PubMed          Journal:  Curr Opin Rheumatol        ISSN: 1040-8711            Impact factor:   5.006


  27 in total

Review 1.  Pediatric antiphospholipid syndrome.

Authors:  Cassyanne L Aguiar; Arzu Soybilgic; Tadej Avcin; Barry L Myones
Journal:  Curr Rheumatol Rep       Date:  2015-04       Impact factor: 4.592

2.  Antiphospholipid antibodies: crossroads between autoimmunity and infections?

Authors:  Savino Sciascia; Massimo Radin; Mario Bazzan; Dario Roccatello
Journal:  Intern Emerg Med       Date:  2017-04-12       Impact factor: 3.397

3.  The spectrum between antiphospholipid syndrome and systemic lupus erythematosus.

Authors:  Nancy Agmon-Levin; Yehuda Shoenfeld
Journal:  Clin Rheumatol       Date:  2014-03       Impact factor: 2.980

4.  Pediatric APS: State of the Art.

Authors:  Arzu Soybilgic; Tadej Avcin
Journal:  Curr Rheumatol Rep       Date:  2020-03-03       Impact factor: 4.592

Review 5.  The role of the gut microbiota in the pathogenesis of antiphospholipid syndrome.

Authors:  William E Ruff; Silvio M Vieira; Martin A Kriegel
Journal:  Curr Rheumatol Rep       Date:  2015-01       Impact factor: 4.592

Review 6.  Anti-phospholipid Antibodies and Smoking: An Overview.

Authors:  Steven R Binder; Christine M Litwin
Journal:  Clin Rev Allergy Immunol       Date:  2017-08       Impact factor: 8.667

7.  Association of early kidney allograft failure with preformed IgA antibodies to β2-glycoprotein I.

Authors:  Jose M Morales; Jose Angel Martinez-Flores; Manuel Serrano; Maria José Castro; Francisco Javier Alfaro; Florencio García; Miguel Angel Martínez; Amado Andrés; Esther González; Manuel Praga; Estela Paz-Artal; Antonio Serrano
Journal:  J Am Soc Nephrol       Date:  2014-07-28       Impact factor: 10.121

8.  Are the autoimmune/inflammatory syndrome induced by adjuvants (ASIA) and the undifferentiated connective tissue disease (UCTD) related to each other? A case-control study of environmental exposures.

Authors:  F Scanzi; L Andreoli; M Martinelli; M Taraborelli; I Cavazzana; N Carabellese; R Ottaviani; F Allegri; F Franceschini; N Agmon-Levin; Y Shoenfeld; Angela Tincani
Journal:  Immunol Res       Date:  2017-02       Impact factor: 4.505

Review 9.  Antiphospholipid antibodies and risk of post-COVID-19 vaccination thrombophilia: The straw that breaks the camel's back?

Authors:  Rossella Talotta; Erle S Robertson
Journal:  Cytokine Growth Factor Rev       Date:  2021-05-28       Impact factor: 7.638

Review 10.  Untangling the Intricacies of Infection, Thrombosis, Vaccination, and Antiphospholipid Antibodies for COVID-19.

Authors:  Nevio Cimolai
Journal:  SN Compr Clin Med       Date:  2021-06-22
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.